GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lophos Holdings Inc (XCNQ:MESC) » Definitions » Equity-to-Asset

Lophos Holdings (XCNQ:MESC) Equity-to-Asset : 0.38 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Lophos Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Lophos Holdings's Total Stockholders Equity for the quarter that ended in Mar. 2024 was C$1.48 Mil. Lophos Holdings's Total Assets for the quarter that ended in Mar. 2024 was C$3.90 Mil.

The historical rank and industry rank for Lophos Holdings's Equity-to-Asset or its related term are showing as below:

XCNQ:MESC's Equity-to-Asset is not ranked *
in the Biotechnology industry.
Industry Median: 0.67
* Ranked among companies with meaningful Equity-to-Asset only.

Lophos Holdings Equity-to-Asset Historical Data

The historical data trend for Lophos Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lophos Holdings Equity-to-Asset Chart

Lophos Holdings Annual Data
Trend Mar22 Mar23 Mar24
Equity-to-Asset
0.49 0.37 0.38

Lophos Holdings Quarterly Data
Dec21 Mar22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only 0.37 0.35 0.41 0.42 0.38

Competitive Comparison of Lophos Holdings's Equity-to-Asset

For the Biotechnology subindustry, Lophos Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lophos Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lophos Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Lophos Holdings's Equity-to-Asset falls into.


;
;

Lophos Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Lophos Holdings's Equity to Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

Equity to Asset (A: Mar. 2024 )=Total Stockholders Equity/Total Assets
=1.479/3.9
=

Lophos Holdings's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=1.479/3.9
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lophos Holdings  (XCNQ:MESC) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Lophos Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Lophos Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lophos Holdings Business Description

Traded in Other Exchanges
N/A
Address
1111 Melville Street, Suite 620, Vancouver, BC, CAN, V6E 3V6
Website
Lophos Holdings Inc is engaged in the y is the cultivation of peyote and the manufacture of Lophophora compounds, including Mescaline, as well as formulation of novel Lophophora-based compounds.
Executives
John Ioannis Karagiannidis Director
Evan Stawnyczy Director

Lophos Holdings Headlines

No Headlines